| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Milk, Human | 30 | 2026 | 100 | 6.230 |
Why?
|
| Breast Neoplasms | 33 | 2025 | 1235 | 4.450 |
Why?
|
| DNA Methylation | 14 | 2021 | 307 | 3.500 |
Why?
|
| Breast Feeding | 8 | 2023 | 166 | 1.810 |
Why?
|
| Biomarkers, Tumor | 9 | 2023 | 527 | 1.600 |
Why?
|
| Lactation | 11 | 2026 | 77 | 1.360 |
Why?
|
| Vegetables | 2 | 2022 | 67 | 1.260 |
Why?
|
| CpG Islands | 8 | 2021 | 219 | 1.180 |
Why?
|
| Receptors, Estrogen | 5 | 2020 | 132 | 1.170 |
Why?
|
| Genes, Tumor Suppressor | 4 | 2014 | 78 | 1.050 |
Why?
|
| Epigenesis, Genetic | 4 | 2020 | 408 | 1.000 |
Why?
|
| Promoter Regions, Genetic | 7 | 2020 | 690 | 0.970 |
Why?
|
| Diet | 4 | 2023 | 540 | 0.960 |
Why?
|
| Leukocytes | 3 | 2021 | 110 | 0.870 |
Why?
|
| Breast | 6 | 2026 | 194 | 0.810 |
Why?
|
| Female | 48 | 2026 | 34420 | 0.750 |
Why?
|
| Cytokines | 3 | 2022 | 965 | 0.730 |
Why?
|
| Fruit | 2 | 2022 | 103 | 0.720 |
Why?
|
| Antibodies, Neutralizing | 2 | 2024 | 220 | 0.670 |
Why?
|
| Infant | 7 | 2024 | 1718 | 0.660 |
Why?
|
| Environmental Exposure | 5 | 2010 | 228 | 0.590 |
Why?
|
| Endocrine Disruptors | 2 | 2025 | 78 | 0.590 |
Why?
|
| Humans | 55 | 2026 | 65831 | 0.570 |
Why?
|
| Adult | 29 | 2025 | 17575 | 0.560 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2023 | 273 | 0.560 |
Why?
|
| Transforming Growth Factor beta2 | 2 | 2015 | 8 | 0.540 |
Why?
|
| Estradiol | 3 | 2010 | 260 | 0.530 |
Why?
|
| Inflammation Mediators | 1 | 2018 | 180 | 0.520 |
Why?
|
| Case-Control Studies | 7 | 2023 | 1146 | 0.510 |
Why?
|
| Estrogens | 3 | 2020 | 115 | 0.490 |
Why?
|
| Triple Negative Breast Neoplasms | 2 | 2014 | 71 | 0.480 |
Why?
|
| Polycyclic Aromatic Hydrocarbons | 3 | 2007 | 18 | 0.480 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2018 | 378 | 0.470 |
Why?
|
| Mass Spectrometry | 4 | 2026 | 296 | 0.470 |
Why?
|
| Early Detection of Cancer | 3 | 2024 | 327 | 0.440 |
Why?
|
| S-Phase Kinase-Associated Proteins | 1 | 2014 | 7 | 0.430 |
Why?
|
| Tandem Mass Spectrometry | 2 | 2023 | 143 | 0.430 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2014 | 32 | 0.430 |
Why?
|
| Neoplasm Invasiveness | 3 | 2014 | 289 | 0.420 |
Why?
|
| Sodium | 2 | 2026 | 60 | 0.420 |
Why?
|
| Biopsy | 2 | 2018 | 463 | 0.420 |
Why?
|
| Potassium | 2 | 2026 | 98 | 0.410 |
Why?
|
| Estrogen Antagonists | 1 | 2013 | 16 | 0.410 |
Why?
|
| Spike Glycoprotein, Coronavirus | 3 | 2024 | 114 | 0.410 |
Why?
|
| Tamoxifen | 1 | 2013 | 42 | 0.400 |
Why?
|
| DNA, Neoplasm | 2 | 2014 | 62 | 0.400 |
Why?
|
| Water Pollutants, Chemical | 3 | 2017 | 43 | 0.400 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2013 | 38 | 0.390 |
Why?
|
| Pregnancy | 6 | 2023 | 2401 | 0.390 |
Why?
|
| rhoA GTP-Binding Protein | 1 | 2013 | 27 | 0.390 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2013 | 29 | 0.390 |
Why?
|
| Benzhydryl Compounds | 1 | 2014 | 61 | 0.390 |
Why?
|
| Phenols | 1 | 2014 | 77 | 0.380 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2013 | 65 | 0.380 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 1 | 2012 | 29 | 0.360 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2012 | 46 | 0.360 |
Why?
|
| Estrogen Receptor alpha | 3 | 2020 | 49 | 0.360 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2013 | 218 | 0.360 |
Why?
|
| Gene Expression Regulation, Neoplastic | 4 | 2020 | 588 | 0.360 |
Why?
|
| Proteomics | 5 | 2024 | 299 | 0.350 |
Why?
|
| Oryzias | 2 | 2010 | 6 | 0.350 |
Why?
|
| Immunoglobulin A | 2 | 2022 | 102 | 0.340 |
Why?
|
| Antibodies, Viral | 2 | 2024 | 329 | 0.330 |
Why?
|
| Middle Aged | 14 | 2024 | 18498 | 0.320 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 4 | 2018 | 157 | 0.310 |
Why?
|
| Immunoglobulin G | 2 | 2022 | 472 | 0.310 |
Why?
|
| Tumor Cells, Cultured | 4 | 2020 | 426 | 0.300 |
Why?
|
| Young Adult | 13 | 2025 | 4882 | 0.290 |
Why?
|
| Carcinogens, Environmental | 1 | 2008 | 6 | 0.290 |
Why?
|
| Biomarkers | 4 | 2026 | 1502 | 0.280 |
Why?
|
| Cell Separation | 2 | 2026 | 147 | 0.280 |
Why?
|
| MCF-7 Cells | 3 | 2026 | 65 | 0.260 |
Why?
|
| Gene Expression | 3 | 2017 | 856 | 0.250 |
Why?
|
| Tumor Suppressor Proteins | 3 | 2014 | 211 | 0.250 |
Why?
|
| Ion-Selective Electrodes | 1 | 2026 | 4 | 0.240 |
Why?
|
| Membrane Proteins | 4 | 2021 | 926 | 0.240 |
Why?
|
| Cellulose | 1 | 2026 | 46 | 0.230 |
Why?
|
| Epithelial Cells | 3 | 2014 | 414 | 0.230 |
Why?
|
| Risk Factors | 7 | 2017 | 5476 | 0.230 |
Why?
|
| Breast Density | 1 | 2025 | 19 | 0.220 |
Why?
|
| Proteome | 3 | 2024 | 153 | 0.220 |
Why?
|
| Thiazines | 1 | 2024 | 2 | 0.210 |
Why?
|
| Vitellogenins | 2 | 2017 | 2 | 0.210 |
Why?
|
| Hazardous Waste | 1 | 2004 | 3 | 0.210 |
Why?
|
| Fuel Oils | 1 | 2004 | 5 | 0.210 |
Why?
|
| Sweetening Agents | 1 | 2024 | 20 | 0.210 |
Why?
|
| Sucrose | 1 | 2024 | 30 | 0.210 |
Why?
|
| alpha-Mannosidase | 1 | 2004 | 5 | 0.210 |
Why?
|
| Immunization, Secondary | 1 | 2024 | 52 | 0.200 |
Why?
|
| DNA | 2 | 2026 | 853 | 0.200 |
Why?
|
| Microfluidics | 1 | 2024 | 26 | 0.200 |
Why?
|
| Saliva | 1 | 2024 | 100 | 0.200 |
Why?
|
| Carbohydrates | 1 | 2004 | 40 | 0.200 |
Why?
|
| beta-Galactosidase | 1 | 2004 | 84 | 0.200 |
Why?
|
| Glutathione S-Transferase pi | 3 | 2014 | 8 | 0.200 |
Why?
|
| Genes, Reporter | 1 | 2004 | 257 | 0.200 |
Why?
|
| Prognosis | 5 | 2020 | 1793 | 0.200 |
Why?
|
| Allergens | 1 | 2023 | 54 | 0.190 |
Why?
|
| Receptors, CCR7 | 1 | 2022 | 9 | 0.190 |
Why?
|
| Cross-Over Studies | 1 | 2023 | 163 | 0.190 |
Why?
|
| Transcriptome | 2 | 2018 | 408 | 0.180 |
Why?
|
| Aged | 6 | 2021 | 15145 | 0.180 |
Why?
|
| Immunoglobulin M | 1 | 2022 | 116 | 0.180 |
Why?
|
| Cell Line, Tumor | 4 | 2015 | 1573 | 0.180 |
Why?
|
| Colostrum | 1 | 2021 | 6 | 0.170 |
Why?
|
| Immunity, Humoral | 1 | 2021 | 40 | 0.170 |
Why?
|
| Leptin | 2 | 2018 | 89 | 0.170 |
Why?
|
| Neoplasm Proteins | 2 | 2013 | 286 | 0.170 |
Why?
|
| Aged, 80 and over | 3 | 2018 | 5681 | 0.170 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2021 | 72 | 0.160 |
Why?
|
| Endonucleases | 1 | 2021 | 84 | 0.160 |
Why?
|
| Immunity, Cellular | 1 | 2021 | 170 | 0.160 |
Why?
|
| Membrane Transport Proteins | 1 | 2021 | 135 | 0.160 |
Why?
|
| Mitochondrial Proteins | 1 | 2021 | 110 | 0.160 |
Why?
|
| Infant, Newborn | 3 | 2022 | 1438 | 0.160 |
Why?
|
| GATA3 Transcription Factor | 1 | 2020 | 16 | 0.160 |
Why?
|
| Hepatocyte Nuclear Factor 3-alpha | 1 | 2020 | 21 | 0.160 |
Why?
|
| Prospective Studies | 4 | 2021 | 3339 | 0.160 |
Why?
|
| Age Factors | 3 | 2014 | 1595 | 0.160 |
Why?
|
| Counseling | 1 | 2022 | 376 | 0.150 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2021 | 345 | 0.150 |
Why?
|
| Electrophoresis | 1 | 2019 | 16 | 0.150 |
Why?
|
| Vaccination | 1 | 2022 | 388 | 0.140 |
Why?
|
| Carcinogenesis | 1 | 2020 | 135 | 0.140 |
Why?
|
| Cell Cycle Proteins | 1 | 2021 | 404 | 0.140 |
Why?
|
| Limit of Detection | 2 | 2020 | 49 | 0.140 |
Why?
|
| Adiponectin | 1 | 2018 | 37 | 0.140 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2022 | 809 | 0.140 |
Why?
|
| Transfection | 2 | 2014 | 700 | 0.140 |
Why?
|
| Chromatography, Liquid | 2 | 2020 | 119 | 0.140 |
Why?
|
| Metal Nanoparticles | 2 | 2010 | 191 | 0.130 |
Why?
|
| Reactive Oxygen Species | 2 | 2010 | 238 | 0.130 |
Why?
|
| Eating | 1 | 2018 | 140 | 0.130 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2017 | 17 | 0.130 |
Why?
|
| Breast Neoplasms, Male | 1 | 2017 | 14 | 0.130 |
Why?
|
| Nanostructures | 1 | 2020 | 187 | 0.130 |
Why?
|
| C-Reactive Protein | 1 | 2018 | 171 | 0.130 |
Why?
|
| Cytoskeletal Proteins | 2 | 2010 | 204 | 0.130 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2018 | 420 | 0.130 |
Why?
|
| Genome, Human | 1 | 2019 | 238 | 0.130 |
Why?
|
| Azacitidine | 2 | 2015 | 15 | 0.130 |
Why?
|
| Weaning | 1 | 2016 | 7 | 0.120 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2010 | 542 | 0.120 |
Why?
|
| Polymers | 1 | 2020 | 332 | 0.120 |
Why?
|
| Feasibility Studies | 1 | 2018 | 593 | 0.120 |
Why?
|
| Specimen Handling | 1 | 2016 | 61 | 0.110 |
Why?
|
| Peptides | 1 | 2020 | 593 | 0.110 |
Why?
|
| Transforming Growth Factor beta1 | 2 | 2012 | 61 | 0.110 |
Why?
|
| Cohort Studies | 1 | 2022 | 2651 | 0.110 |
Why?
|
| Massachusetts | 3 | 2018 | 2158 | 0.110 |
Why?
|
| Cyclin D2 | 1 | 2015 | 8 | 0.110 |
Why?
|
| Phosphorylation | 2 | 2014 | 963 | 0.110 |
Why?
|
| Polymerase Chain Reaction | 3 | 2017 | 514 | 0.110 |
Why?
|
| Pilot Projects | 1 | 2018 | 1029 | 0.110 |
Why?
|
| Melatonin | 1 | 2015 | 66 | 0.110 |
Why?
|
| Cyclin D1 | 1 | 2014 | 17 | 0.110 |
Why?
|
| DNA-Binding Proteins | 1 | 2021 | 1226 | 0.110 |
Why?
|
| Cyclin-Dependent Kinase 2 | 1 | 2014 | 19 | 0.110 |
Why?
|
| Cell Proliferation | 2 | 2020 | 1044 | 0.110 |
Why?
|
| Radiation Tolerance | 1 | 2015 | 56 | 0.110 |
Why?
|
| Chlamydia trachomatis | 1 | 2014 | 60 | 0.110 |
Why?
|
| Neoplasm Grading | 1 | 2014 | 102 | 0.110 |
Why?
|
| Bacterial Adhesion | 1 | 2014 | 65 | 0.100 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 2014 | 15 | 0.100 |
Why?
|
| Protein Isoforms | 1 | 2015 | 201 | 0.100 |
Why?
|
| Serine | 1 | 2014 | 90 | 0.100 |
Why?
|
| Proteins | 1 | 2020 | 764 | 0.100 |
Why?
|
| Solid Phase Extraction | 1 | 2014 | 10 | 0.100 |
Why?
|
| Risk | 1 | 2015 | 375 | 0.100 |
Why?
|
| ErbB Receptors | 1 | 2014 | 128 | 0.100 |
Why?
|
| Transcriptional Activation | 1 | 2014 | 196 | 0.100 |
Why?
|
| Estrogens, Non-Steroidal | 1 | 2014 | 38 | 0.100 |
Why?
|
| Adolescent | 5 | 2020 | 6367 | 0.100 |
Why?
|
| Electrophoresis, Gel, Two-Dimensional | 2 | 2024 | 37 | 0.100 |
Why?
|
| Gene Expression Profiling | 1 | 2017 | 799 | 0.100 |
Why?
|
| Antidepressive Agents | 1 | 2015 | 244 | 0.100 |
Why?
|
| Mammaplasty | 1 | 2014 | 47 | 0.100 |
Why?
|
| 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine | 1 | 2013 | 6 | 0.100 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2013 | 42 | 0.100 |
Why?
|
| Matrix Metalloproteinase 1 | 1 | 2013 | 9 | 0.100 |
Why?
|
| Head and Neck Neoplasms | 1 | 2015 | 166 | 0.100 |
Why?
|
| Up-Regulation | 1 | 2014 | 377 | 0.100 |
Why?
|
| Antigens, Neoplasm | 1 | 2013 | 134 | 0.090 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2013 | 84 | 0.090 |
Why?
|
| Lipocalins | 1 | 2012 | 4 | 0.090 |
Why?
|
| Lipocalin-2 | 1 | 2012 | 8 | 0.090 |
Why?
|
| Cell Division | 2 | 2004 | 451 | 0.090 |
Why?
|
| Chitinase-3-Like Protein 1 | 1 | 2012 | 14 | 0.090 |
Why?
|
| Risk Assessment | 3 | 2018 | 2115 | 0.090 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 2012 | 20 | 0.090 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2013 | 297 | 0.090 |
Why?
|
| Acute-Phase Proteins | 1 | 2012 | 35 | 0.090 |
Why?
|
| Cell Cycle | 1 | 2014 | 398 | 0.090 |
Why?
|
| Adipokines | 1 | 2012 | 38 | 0.090 |
Why?
|
| Breast Diseases | 1 | 2012 | 45 | 0.090 |
Why?
|
| Lectins | 1 | 2012 | 43 | 0.090 |
Why?
|
| Gravidity | 1 | 2012 | 11 | 0.090 |
Why?
|
| Host-Pathogen Interactions | 1 | 2014 | 279 | 0.090 |
Why?
|
| Milk Proteins | 1 | 2012 | 45 | 0.090 |
Why?
|
| Primary Prevention | 1 | 2012 | 140 | 0.090 |
Why?
|
| Gold | 2 | 2010 | 235 | 0.090 |
Why?
|
| Repressor Proteins | 1 | 2013 | 351 | 0.090 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 2 | 2023 | 185 | 0.090 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2012 | 449 | 0.090 |
Why?
|
| Cell Movement | 1 | 2013 | 484 | 0.080 |
Why?
|
| Retinol-Binding Proteins, Cellular | 1 | 2010 | 1 | 0.080 |
Why?
|
| RNA Interference | 1 | 2014 | 647 | 0.080 |
Why?
|
| Fishes | 1 | 2010 | 23 | 0.080 |
Why?
|
| Animals | 8 | 2026 | 21492 | 0.080 |
Why?
|
| Cations | 1 | 2010 | 64 | 0.080 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2012 | 344 | 0.080 |
Why?
|
| CARD Signaling Adaptor Proteins | 1 | 2010 | 66 | 0.080 |
Why?
|
| DNA Damage | 2 | 2010 | 298 | 0.080 |
Why?
|
| Cadherins | 1 | 2010 | 90 | 0.080 |
Why?
|
| Surveys and Questionnaires | 2 | 2015 | 2790 | 0.080 |
Why?
|
| Antigens, CD | 1 | 2010 | 344 | 0.070 |
Why?
|
| Depression | 1 | 2015 | 910 | 0.070 |
Why?
|
| Polybrominated Biphenyls | 1 | 2007 | 3 | 0.070 |
Why?
|
| Hydrocarbons, Chlorinated | 1 | 2007 | 11 | 0.070 |
Why?
|
| Petroleum | 1 | 2007 | 10 | 0.070 |
Why?
|
| Reproducibility of Results | 2 | 2026 | 1719 | 0.070 |
Why?
|
| Perfume | 1 | 2007 | 1 | 0.070 |
Why?
|
| Polycyclic Compounds | 1 | 2007 | 2 | 0.070 |
Why?
|
| Fluorocarbons | 1 | 2008 | 56 | 0.060 |
Why?
|
| Environmental Pollutants | 1 | 2008 | 97 | 0.060 |
Why?
|
| Pesticides | 1 | 2007 | 58 | 0.060 |
Why?
|
| Cell Adhesion Molecules | 1 | 2006 | 95 | 0.060 |
Why?
|
| Male | 6 | 2024 | 31403 | 0.060 |
Why?
|
| Parabens | 1 | 2025 | 6 | 0.060 |
Why?
|
| Cell Adhesion | 1 | 2026 | 218 | 0.060 |
Why?
|
| Soil Pollutants | 1 | 2004 | 25 | 0.050 |
Why?
|
| Radiometry | 1 | 2004 | 39 | 0.050 |
Why?
|
| RNA, Messenger | 1 | 2010 | 1583 | 0.050 |
Why?
|
| Response Elements | 1 | 2004 | 41 | 0.050 |
Why?
|
| Receptors, Aryl Hydrocarbon | 1 | 2004 | 16 | 0.050 |
Why?
|
| Signal Transduction | 1 | 2014 | 3170 | 0.050 |
Why?
|
| Binding, Competitive | 1 | 2004 | 96 | 0.050 |
Why?
|
| Plant Lectins | 1 | 2004 | 7 | 0.050 |
Why?
|
| Acetylglucosamine | 1 | 2004 | 11 | 0.050 |
Why?
|
| Galactose | 1 | 2004 | 12 | 0.050 |
Why?
|
| Heat-Shock Proteins | 1 | 2004 | 71 | 0.050 |
Why?
|
| Lactose | 1 | 2004 | 10 | 0.050 |
Why?
|
| Antibody Formation | 1 | 2024 | 111 | 0.050 |
Why?
|
| Postpartum Period | 2 | 2018 | 190 | 0.050 |
Why?
|
| Carbohydrate Metabolism | 1 | 2004 | 49 | 0.050 |
Why?
|
| Quality Control | 2 | 2017 | 79 | 0.050 |
Why?
|
| Plant Proteins | 1 | 2004 | 94 | 0.050 |
Why?
|
| Time Factors | 1 | 2010 | 3777 | 0.050 |
Why?
|
| Fluorescent Dyes | 1 | 2004 | 204 | 0.040 |
Why?
|
| Xenobiotics | 1 | 2002 | 13 | 0.040 |
Why?
|
| Endocrine System | 1 | 2002 | 16 | 0.040 |
Why?
|
| Recombinant Proteins | 1 | 2004 | 710 | 0.040 |
Why?
|
| Receptors, Cell Surface | 1 | 2004 | 432 | 0.040 |
Why?
|
| HeLa Cells | 2 | 2014 | 541 | 0.040 |
Why?
|
| Mothers | 1 | 2024 | 281 | 0.040 |
Why?
|
| Public Health | 1 | 2002 | 188 | 0.040 |
Why?
|
| Spectrometry, Mass, Electrospray Ionization | 1 | 2020 | 91 | 0.040 |
Why?
|
| Fas Ligand Protein | 1 | 2018 | 40 | 0.030 |
Why?
|
| Fibroblast Growth Factors | 1 | 2018 | 77 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2025 | 2739 | 0.030 |
Why?
|
| Cyprinidae | 1 | 2017 | 4 | 0.030 |
Why?
|
| Ethinyl Estradiol | 1 | 2017 | 9 | 0.030 |
Why?
|
| Interleukin-1beta | 1 | 2018 | 274 | 0.030 |
Why?
|
| Amino Acid Sequence | 1 | 2020 | 1590 | 0.030 |
Why?
|
| Ovarian Neoplasms | 1 | 2017 | 170 | 0.030 |
Why?
|
| Turkey | 1 | 2014 | 13 | 0.030 |
Why?
|
| NIH 3T3 Cells | 1 | 2014 | 99 | 0.030 |
Why?
|
| Apoptosis | 1 | 2020 | 1100 | 0.030 |
Why?
|
| Long Interspersed Nucleotide Elements | 1 | 2014 | 18 | 0.030 |
Why?
|
| Colorectal Neoplasms | 1 | 2017 | 290 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 2017 | 462 | 0.030 |
Why?
|
| Neoplasm Staging | 1 | 2015 | 553 | 0.030 |
Why?
|
| Software | 1 | 2017 | 401 | 0.030 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2014 | 269 | 0.020 |
Why?
|
| Women's Health | 1 | 2015 | 376 | 0.020 |
Why?
|
| Oxidative Stress | 2 | 2007 | 323 | 0.020 |
Why?
|
| United States | 3 | 2015 | 8186 | 0.020 |
Why?
|
| Prostatic Neoplasms | 1 | 2017 | 502 | 0.020 |
Why?
|
| Parity | 1 | 2012 | 71 | 0.020 |
Why?
|
| Congresses as Topic | 1 | 2012 | 78 | 0.020 |
Why?
|
| Kallikreins | 1 | 2012 | 9 | 0.020 |
Why?
|
| Interdisciplinary Communication | 1 | 2012 | 106 | 0.020 |
Why?
|
| Comet Assay | 1 | 2010 | 11 | 0.020 |
Why?
|
| Disease Models, Animal | 2 | 2012 | 2329 | 0.020 |
Why?
|
| Evidence-Based Medicine | 1 | 2012 | 464 | 0.020 |
Why?
|
| Lung Neoplasms | 1 | 2017 | 712 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2014 | 737 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2015 | 2500 | 0.020 |
Why?
|
| Biological Transport | 1 | 2010 | 292 | 0.020 |
Why?
|
| Surface Properties | 1 | 2010 | 283 | 0.020 |
Why?
|
| Hydrophobic and Hydrophilic Interactions | 1 | 2010 | 281 | 0.020 |
Why?
|
| Models, Theoretical | 1 | 2010 | 274 | 0.020 |
Why?
|
| Cell Survival | 1 | 2010 | 588 | 0.020 |
Why?
|
| Maternal Exposure | 1 | 2008 | 43 | 0.020 |
Why?
|
| United States Environmental Protection Agency | 1 | 2007 | 7 | 0.020 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 1 | 2007 | 40 | 0.020 |
Why?
|
| Xylenes | 1 | 2007 | 4 | 0.020 |
Why?
|
| Benzopyrans | 1 | 2007 | 6 | 0.020 |
Why?
|
| Tetrahydronaphthalenes | 1 | 2007 | 3 | 0.020 |
Why?
|
| Environmental Monitoring | 1 | 2008 | 155 | 0.020 |
Why?
|
| Neoplasms | 2 | 2010 | 1377 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2012 | 1635 | 0.010 |
Why?
|
| Metals, Heavy | 1 | 2002 | 8 | 0.010 |
Why?
|
| Organic Chemicals | 1 | 2002 | 27 | 0.010 |
Why?
|
| Gonadal Steroid Hormones | 1 | 2002 | 36 | 0.010 |
Why?
|
| Infertility, Male | 1 | 2002 | 57 | 0.010 |
Why?
|
| Drug Interactions | 1 | 2002 | 126 | 0.010 |
Why?
|
| Mice | 1 | 2014 | 11185 | 0.010 |
Why?
|
| Nervous System Diseases | 1 | 2002 | 109 | 0.010 |
Why?
|
| Spermatozoa | 1 | 2002 | 267 | 0.010 |
Why?
|
| Disease Progression | 1 | 2002 | 1229 | 0.010 |
Why?
|